GLOBAL FACTOR VIII DEFICIENCY TREATMENT MARKET ANALYSIS

Market News

The Global factor VIII deficiency treatment market growth is driven by an increase in approvals by various regulatory authorities such as U.S. FDA. For instance, on February 23, 2023, Sanofi, a France-based multinational pharmaceutical and healthcare company, announced that they have received U.S. FDA approval for its efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy, useful for the treatment of hemophilia A in adults

Global Factor VIII Deficiency Treatment Market Segmentation:

The Global factor VIII deficiency treatment market report is segmented into product type, and distribution channel

Based on product type, the market is segmented into plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, biologic (hemlibra), and desmopressin. Out of which, the recombinant coagulation factor concentrates segment is expected to dominate the Global factor VIII deficiency treatment market during the forecast period and this is attributed to an increase in the product launches by key market players.

Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Out of which, the hospital segment is expected to dominate the market over the forecast period and this is attributed to an increase in the number of hospitals globally.

Among all segmentation, the product type segment has the highest potential due to an increase in the number of product approvals. For instance, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare for the anti-coagulation factor IXa/X humanized bispecific monoclonal antibody/coagulation factor VIII substitute Hemlibra [generic name: emicizumab (genetical recombination)] for patients with acquired hemophilia A.

Global Factor VIII Deficiency Treatment Market Cross Sectional Analysis:

In the product type segment, Biologic segment held a dominant position in the North America region due to an increase in the inorganic strategies between key market players. For instance, in June 2020, CSL Behring, a U.S.-based biopharmaceutical company, announced that it had acquired exclusive global license rights to commercialize AMT-061 (etranacogene dezaparvovec), a biologic based drug candidate indicated to treat hemophilia from Uniqure NV, a Netherlands based pharmaceutical company